Role of Exenatide in NASH-a Pilot Study

NCT00650546 · Completed

Last updated 2026-05-28

This clinical trial tests whether the medication exenatide can improve liver health in adults with nonalcoholic fatty liver disease.

Status Completed The study has finished.

Phase Phase2, Phase3

Type Interventional (clinical trial)

Design open-label (no blinding) study

Participants 8 people

Who can join Ages 18–99 · all sexes

Timeline Started 2006-08 · est. completion 2010-08

Where 3 sites · United States

What this study is testing ClinicalTrials.gov NCT00650546 ↗

Description as written by the study sponsor.

We hypothesize that exenatide (Byetta), a GLP-1 agonist administered subcutaneously for 24-28 weeks improves liver histology in diabetic patients with biopsy-proven NASH.

Treatments tested

Exenatide also known as Byetta Drug

5 mcg twice a day titrated to 10 mcg twice a day

Main thing measured	Number of Patients With Improvement in Liver Histology After Treatment With Exenatide
Sponsor	Indiana University
Conditions studied	Nonalcoholic Fatty Liver Disease
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00650546 ↗